Pneumonia: The impact of risk factors on the outcome of treatment with meropenem and ceftazidime

Journal of Chemotherapy

Volumn 10, Issue 1, 1998, Pages 35-46

  Finch, R G ^a,c   Pemberton, K ^b   Gildon, K M ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Ceftazidime; Meropenem; Pneumonia; Risk factors

Indexed keywords

CEFTAZIDIME; MEROPENEM;

ADULT; AGE; ALBUMIN BLOOD LEVEL; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; ENTEROBACTERIACEAE; FEMALE; GENDER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; UREA BLOOD LEVEL;

EID: 0031914838     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1998.10.1.35     Document Type: Article

References (24)

1. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134-141.
2. Marrie TJ. Epidemiology of community-acquired pneumonia in the elderly. Semin Resp Infect 1990; 5: 260-268.
3. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
4. Sullivan RJ, Dowdle WR, Marine WM, Hierholzer JC. Adult pneumonia in a general hospital. Arch Intern Med 1972; 129: 935-942.
5. Macfarlane JT, Finch RG, Ward MJ, Macrae AD. Hospital study of adult community-acquired pneumonia. Lancet 1982; 2: 255-258.
6. Woodhead MA, Macfarlane JT, Rodgers FG, Laverick A, Pilkington R, Macrae AD. Aetiology and outcome of severe community-acquired pneumonia. J Infect 1985; 10: 204-210.
7. Research Committee of the British Thoracic Society and the Public Health Laboratory Service. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. Q J Med 1987; 62: 195-220.
8. Fine MJ, Smith DN, Singer DE. Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study. Am J Med 1990; 89: 713-721.
9. Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991; 115: 428-436.
10. Fine MJ, Singer DE, Hanusa BH, Lave JR, Kapoor WN. Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database. Am J Med 1993; 94: 153-159.
11. Fine MJ, Hough LJ, Medsger AR, et al. The hospital admission decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Cohort Study. Arch Intern Med 1997; 157: 36-44.
12. Niederman MS, Bass JB, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418-1426.
13. Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995; 35 (suppl A): 1-18.
14. Mouton YJ, Beuscart C and the Meropenem Study Group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995; 35 (suppl A): 145-156.
15. Colardyn F, Faulkner KL, on behalf of the Meropenem Serious Infection Study Group. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J Antimicrob Chemother 1996; 38: 523-537.
16. Sieger B, Berman SJ, Geckler RW, et al. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin. A randomized study. Crit Care Med 1997; 25: 1663-1670.
17. Romanelli G, Cravarezza P, Ragni G, Franchino L. Meropenem e.v. nelle infezioni delle basse vie respiratorie: confronto multicentrico. Farmaci e Terapia 1995; 12: 1-9.
18. Herman SJ, Sieger B, Geckler RW, Farkas SA. A comparative study of meropenem and ceftazidime in the treatment of patients hospitalized with community-acquired pneumonia. Curr Ther Res 1997; 58: 903-916.
19. Örtqvist Å. Initial investigation and treatment of the patient with severe community-acquired pneumonia. Semin Respir Infect 1994; 9: 166-179.
20. Mandell LA. Community-acquired pneumonia: etiology, epidemiology, and treatment. Chest 1995; 108: 35S-42S.
21. Mandell LA, Marrie TJ, Niederman MS, the Canadian Hospital Acquired Pneumonia Consensus Conference Group. Initial antimicrobial treatment of hospital-acquired pneumonia in adults: a conference report. Can J Infect Dis 1993; 4: 317-321.
22. Craven DE, Barber TW, Steger KA, Montecalvo MA. Nosocomial pneumonia in the 1990s: update of epidemiology and risk factors. Semin Resp Infect 1990; 5: 157-172.
23. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. A consensus statement. Am J Respir Crit Care Med 1995; 153: 1711-725.
24. Niederman MS. Approach to pneumonia in the elderly nursing home patient. In: Niederman MS, Sarosi GA, Glassroth J, eds. Respiratory Infections. Philadelphia: WB Saunders, 1994: 233-240.